Last reviewed · How we verify

NCT05382208: DEPTH

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

Active, enrolled Phase 2 Last updated 22 January 2026
What this trial tests

Phase 2 trial testing Doxycycline in Emphysema in 133 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
22 August 2022
Primary endpoint
1 February 2027
1 February 2027

Quick facts

Lead sponsorWeill Medical College of Cornell University
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment133
Start date22 August 2022
Primary completion1 February 2027
Estimated completion1 February 2027
Sites20 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Weill Medical College of Cornell University

Who can join

30 and older, any sex, with Emphysema or HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Pathogenesis and management of emphysema in people with HIV.
    Kreniske JS, Kaner RJ, Glesby MJ. · · 2023 · cited 2× · PMID 37848398 · DOI 10.1080/17476348.2023.2272702
  2. Premature Aging of the Airway Epithelium in Chronic Obstructive Pulmonary Disease in People Living with HIV.
    Kaner RJ. · · 2022 · cited 2× · PMID 35579631 · DOI 10.1164/rccm.202204-0743ed
  3. Pulmonary Immunocompromise in Human Immunodeficiency Virus Disease.
    Attia EF, Maleche-Obimbo E, Ellington LE, North CM. · · 2025 · cited 1× · PMID 39890288 · DOI 10.1016/j.ccm.2024.10.014

Verify or expand the search:

Other trials of Doxycycline

Trials testing the same drug.

Other recruiting trials for Emphysema

Currently open trials in the same condition.

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05382208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing